{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:23Z","timestamp":1793968283508,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["CellFit, #326811"],"award-info":[{"award-number":["CellFit, #326811"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["#326300"],"award-info":[{"award-number":["#326300"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["#297910"],"award-info":[{"award-number":["#297910"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["#272795"],"award-info":[{"award-number":["#272795"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["#144385"],"award-info":[{"award-number":["#144385"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["#223171"],"award-info":[{"award-number":["#223171"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["#2022503"],"award-info":[{"award-number":["#2022503"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["#2019062"],"award-info":[{"award-number":["#2019062"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["#2023600"],"award-info":[{"award-number":["#2023600"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Western Norway Regional Health Authority","doi-asserted-by":"publisher","award":["MyCAR"],"award-info":[{"award-number":["MyCAR"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016242","name":"Norwegian Childhood Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102930","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:13:36Z","timestamp":1781136816000},"page":"102930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-clinical validation of OSCAR-3 mRNA-based CAR T cells for targeting osteosarcomas"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3130-4352","authenticated-orcid":false,"given":"Nadia","family":"Mensali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Joaquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3514-3202","authenticated-orcid":false,"given":"Constance","family":"de Montlaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-8710","authenticated-orcid":false,"given":"Nicholas Paul","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3265-9897","authenticated-orcid":false,"given":"Thomas Olsen","family":"Nesset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-3223","authenticated-orcid":false,"given":"Ola","family":"Myklebost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5254-2173","authenticated-orcid":false,"given":"Anna","family":"Pasetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Winther","family":"Gunnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Gelebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-3536","authenticated-orcid":false,"given":"Else Marit","family":"Inderberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-1746","authenticated-orcid":false,"given":"S\u00e9bastien","family":"W\u00e4lchli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcyt.2026.102930_bib0001","first-page":"1500","article-title":"Survival of patients with primary osteosarcoma and lung metastases","volume":"23","author":"Li","year":"2018","journal-title":"J buon."},{"issue":"11","key":"10.1016\/j.jcyt.2026.102930_bib0002","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.18103\/mra.v12i11.6000","article-title":"Osteosarcoma: A comprehensive review of model systems and experimental therapies","volume":"12","author":"Robbins","year":"2024","journal-title":"Med Res Arch."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102930_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2020.10.137","article-title":"Survival after pulmonary metastasectomy for relapsed osteosarcoma","volume":"163","author":"Liu","year":"2022","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102930_bib0004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/cancers16020275","article-title":"Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group","volume":"16","author":"Mettmann","year":"2024","journal-title":"Cancers (Basel)."},{"issue":"22","key":"10.1016\/j.jcyt.2026.102930_bib0005","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New Horizons in the Treatment of Osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.jcyt.2026.102930_bib0006","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3390\/biomedicines13030664","article-title":"Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials","volume":"13","author":"Sergi","year":"2025","journal-title":"Biomedicines."},{"key":"10.1016\/j.jcyt.2026.102930_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1290762","article-title":"Current status and future challenges of CAR-T cell therapy for osteosarcoma","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102930_bib0008","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1038\/s41467-023-39097-x","article-title":"ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma","volume":"14","author":"Mensali","year":"2023","journal-title":"Nat Commun."},{"issue":"6","key":"10.1016\/j.jcyt.2026.102930_bib0009","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.ymthe.2024.04.009","article-title":"Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer","volume":"32","author":"Maggadottir","year":"2024","journal-title":"Mol Ther."},{"issue":"8","key":"10.1016\/j.jcyt.2026.102930_bib0010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00262-019-02356-2","article-title":"Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy","volume":"68","author":"Mensali","year":"2019","journal-title":"Cancer Immunol Immunother."},{"issue":"11","key":"10.1016\/j.jcyt.2026.102930_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027930","article-title":"A practical approach to T-cell receptor cloning and expression","volume":"6","author":"W\u00e4lchli","year":"2011","journal-title":"PLoS One."},{"issue":"1-2","key":"10.1016\/j.jcyt.2026.102930_bib0012","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-1759(01)00506-3","article-title":"mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)","volume":"259","author":"Saeb\u00f8e-Larssen","year":"2002","journal-title":"J Immunol Methods"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102930_bib0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/07357900802491477","article-title":"Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases","volume":"27","author":"Yuan","year":"2009","journal-title":"Cancer Invest."},{"issue":"4","key":"10.1016\/j.jcyt.2026.102930_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010702","article-title":"Tailoring CAR surface density and dynamics to improve CAR-T cell therapy","volume":"13","author":"Hinckley-Boned","year":"2025","journal-title":"J Immunother Cancer."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102930_bib0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4049\/jimmunol.164.1.208","article-title":"Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers","volume":"164","author":"Slifka","year":"2000","journal-title":"J Immunol."},{"issue":"5271","key":"10.1016\/j.jcyt.2026.102930_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.273.5271.104","article-title":"T cell activation determined by T cell receptor number and tunable thresholds","volume":"273","author":"Viola","year":"1996","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102930_bib0017","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity."},{"issue":"6","key":"10.1016\/j.jcyt.2026.102930_bib0018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"issue":"18","key":"10.1016\/j.jcyt.2026.102930_bib0019","first-page":"5302","article-title":"Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen","volume":"48","author":"Bruland","year":"1988","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102930_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol Res."},{"issue":"14","key":"10.1016\/j.jcyt.2026.102930_bib0021","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.jcyt.2026.102930_bib0022","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat Med."},{"issue":"9","key":"10.1016\/j.jcyt.2026.102930_bib0023","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/ijms22094320","article-title":"Pharmacologic Control of CAR T Cells","volume":"22","author":"Caulier","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102930_bib0024","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102930_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102930_bib0026","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s44321-025-00205-7","article-title":"Safe CAR-T: shedding light on CAR-related T-cell malignancies","volume":"17","author":"Liao","year":"2025","journal-title":"EMBO Mol Med."},{"issue":"8","key":"10.1016\/j.jcyt.2026.102930_bib0027","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/cancers11081198","article-title":"Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance","volume":"11","author":"Wiesinger","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102930_bib0028","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.jcyt.2026.102930_bib0029","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood-2024-203585","article-title":"Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease","volume":"144","author":"Miljkovic","year":"2024","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102930_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102805","article-title":"mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells","volume":"37","author":"Kahwaji","year":"2026","journal-title":"Mol Ther Nucleic Acids."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102930_bib0031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol."},{"issue":"5","key":"10.1016\/j.jcyt.2026.102930_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/14653249.2010.542461","article-title":"Transiently redirected T cells for adoptive transfer","volume":"13","author":"Alm\u00e5sbak","year":"2011","journal-title":"Cytotherapy."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:23:01Z","timestamp":1793967781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1465324926008911"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102930","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical validation of OSCAR-3 mRNA-based CAR T cells for targeting osteosarcomas","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102930"}}